Quoin Pharmaceuticals has filed a U.S. patent application for novel topical formulations to treat several skin diseases, including Netherton Syndrome (NS).
Quoin’s lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin’s open Investigational New Drug (IND) application with the US Food and Drug Administration (FDA).
QRX003 is also currently being tested in a pediatric NS patient at the Children’s Hospital in Dublin, Ireland. The Company intends to expand this study to include additional children with NS in Spain, the United Kingdom, and potentially other countries.
The Company has recently reported positive initial clinical data from the two open-label studies for which data is available. This patent application also includes Peeling Skin Syndrome, for which Quoin has an ongoing Investigator Clinical Study in a pediatric patient in New Zealand. There are currently no FDA-approved treatments for either Netherton Syndrome or Peeling Skin Syndrome.
Three Clinical Trials Evaluating QRX003
Quoin is currently enrolling patients in three clinical trials being conducted under its open Investigational New Drug (IND) application, evaluating its QRX003 topical lotion as a potential treatment for Netherton Syndrome as well as in an Investigator-led pediatric study. To date, Quoin remains the only company actively recruiting and testing subjects in multiple NS clinical trials that are being conducted under an open IND.
“While we are fully focused on completing clinical testing for QRX003 in NS, we are also taking multiple steps to ensure that we have the broadest and most extensive patent protection around the product for this disease as well for other rare skin disease applications that we are pursuing or intend to pursue. If granted, this application would provide broad patent protection for our product until 2045,” says Dr. Michael Myers, Chief Executive Officer of Quoin in a news release.
To find out more about Quoin’s clinical studies relating to Netherton Syndrome, please visit http://www.nethertonsyndromeclinicaltrials.com/.
